J B Chemicals & Pharmaceuticals Ltd

J B Chemicals & Pharmaceuticals Ltd

₹ 2,193 0.63%
22 May - close price
About

J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]

Key Points

Revenue Split H1FY24
Domestic Formulations - 55%
Export Formulations - 30%
Contract Manufacturing - 13%
APIs - 2% [1]

  • Market Cap 35,232 Cr.
  • Current Price 2,193
  • High / Low 2,225 / 1,603
  • Stock P/E 48.3
  • Book Value 259
  • Dividend Yield 0.71 %
  • ROCE 25.8 %
  • ROE 19.2 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 30.7%
  • Promoter holding has increased by 1.25% over last quarter.

Cons

  • Stock is trading at 8.46 times its book value
  • Promoter holding has decreased over last 3 years: -5.13%
  • Working capital days have increased from 108 days to 191 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
762 896 882 845 862 1,004 1,001 963 949 1,094 1,085 1,065 904
599 664 638 621 664 724 730 709 723 793 775 769 703
Operating Profit 164 232 244 223 198 280 271 255 226 301 310 296 201
OPM % 21% 26% 28% 26% 23% 28% 27% 26% 24% 28% 29% 28% 22%
5 6 8 7 17 6 10 8 14 15 15 18 -15
Interest 14 12 10 12 9 6 2 3 1 1 1 2 1
Depreciation 32 31 32 34 41 41 42 42 46 43 44 45 50
Profit before tax 122 194 209 184 165 240 237 218 193 272 279 267 135
Tax % 28% 27% 28% 27% 23% 26% 26% 25% 25% 25% 26% 26% 25%
88 142 151 134 126 177 175 162 146 202 208 198 101
EPS in Rs 5.66 9.19 9.72 8.61 8.13 11.39 11.24 10.45 9.36 12.97 13.27 12.63 6.31
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,144 1,210 1,344 1,408 1,643 1,775 2,043 2,424 3,149 3,484 3,918 4,148
964 1,004 1,112 1,191 1,337 1,397 1,482 1,881 2,454 2,587 2,886 3,040
Operating Profit 180 206 232 218 306 378 560 543 696 897 1,032 1,107
OPM % 16% 17% 17% 15% 19% 21% 27% 22% 22% 26% 26% 27%
11 58 50 37 41 41 112 39 10 37 38 33
Interest 7 11 5 3 5 3 7 5 36 44 12 6
Depreciation 39 41 47 57 56 66 69 73 114 138 171 182
Profit before tax 146 212 230 194 287 349 597 505 555 752 887 952
Tax % 31% 23% 20% 28% 32% 22% 25% 24% 26% 26% 26% 26%
100 163 184 139 194 272 449 386 410 553 660 709
EPS in Rs 5.92 9.58 10.85 8.28 12.05 17.60 28.98 24.93 26.48 35.61 42.37 44.19
Dividend Payout % 118% 26% 5% 12% 21% 31% 28% 33% 34% 34% 37% 21%
Compounded Sales Growth
10 Years: 13%
5 Years: 15%
3 Years: 10%
TTM: 6%
Compounded Profit Growth
10 Years: 18%
5 Years: 13%
3 Years: 22%
TTM: 14%
Stock Price CAGR
10 Years: 33%
5 Years: 25%
3 Years: 31%
1 Year: 30%
Return on Equity
10 Years: 18%
5 Years: 19%
3 Years: 20%
Last Year: 19%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 17 17 17 17 16 15 15 15 15 16 16 16
Reserves 978 1,167 1,347 1,425 1,464 1,420 1,794 2,119 2,465 2,908 3,418 4,143
127 193 49 29 26 29 45 55 572 378 28 2
365 270 262 294 286 349 376 412 495 687 804 807
Total Liabilities 1,487 1,648 1,674 1,765 1,792 1,814 2,231 2,601 3,547 3,988 4,265 4,969
329 440 679 640 621 651 634 1,277 1,901 2,004 1,968 1,898
CWIP 55 135 4 17 15 16 26 19 55 76 63 61
Investments 552 479 411 434 457 403 678 13 206 388 345 765
552 594 580 674 699 743 894 1,293 1,385 1,519 1,889 2,244
Total Assets 1,487 1,648 1,674 1,765 1,792 1,814 2,231 2,601 3,547 3,988 4,265 4,969

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
127 140 201 123 194 276 315 170 626 801 902 704
-112 -26 -45 -21 -28 24 -231 2 -962 -404 -296 -586
-1 -100 -184 -60 -156 -306 -87 -138 357 -385 -580 -123
Net Cash Flow 13 15 -28 43 11 -6 -3 34 20 11 27 -5
Free Cash Flow 56 -63 48 94 153 205 315 -529 -138 540 783 623
CFO/OP 91% 94% 107% 75% 85% 97% 81% 56% 104% 104% 107% 87%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 84 82 72 78 68 71 70 84 67 72 76 69
Inventory Days 122 146 138 145 149 159 181 178 134 155 147 192
Days Payable 63 71 68 75 72 97 97 97 75 110 114 110
Cash Conversion Cycle 143 158 142 148 146 133 153 164 127 117 109 151
Working Capital Days 16 38 75 93 91 81 91 122 81 55 79 191
ROCE % 13% 15% 14% 11% 18% 23% 33% 23% 22% 25% 26% 26%

Insights

In beta
Mar 2011 Mar 2016 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Dec 2025
Medical Representative Productivity (PCPM)
INR Lakhs per month ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Number of Brands in Top 300 (IPM)
Count ・Standalone data
Field Force Strength (Medical Representatives)
Count ・Standalone data
Cardiac Therapy Market Rank (IPM)
Rank ・Standalone data
India Distribution Locations
Count ・Standalone data
Lozenge Manufacturing Global Rank
Rank
Annual New Product Launches (Domestic)
Count ・Standalone data
Domestic Formulations Volume Growth
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
53.91% 53.86% 53.83% 53.78% 53.77% 53.74% 53.66% 47.84% 47.73% 47.56% 47.55% 48.80%
9.53% 10.05% 10.35% 11.06% 12.17% 13.63% 14.64% 18.30% 17.77% 15.31% 14.88% 16.33%
18.65% 18.58% 18.53% 18.38% 17.61% 16.81% 16.40% 18.71% 19.62% 22.83% 23.35% 21.38%
0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
17.90% 17.50% 17.27% 16.78% 16.42% 15.80% 15.29% 15.13% 14.87% 14.31% 14.21% 13.48%
No. of Shareholders 55,96560,81763,23063,89266,95362,74362,08163,94870,06471,95769,33874,043

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls